Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is approximately 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The current opinion among 11 TipRanks analysts is for a modest Buy rating of shares in CVS Health, with an average price target of $84.

The analysts priced targets range from a high of $101 to a low of sixty one dolars.

From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The retail or Long Term Care segment includes selling of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in offering management as well as administrative services. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.